Auxiliary treatment of pregabalin and gabapentin for postherpetic neuralgia
XING Ze-ting,WANG Mei,GUO Yu-fu,HUA Fu-zhou,ZHANG Xue-xue,ZHANG Da-ying
2013-01-01
Abstract:Objective To assess the efficacy and adverse events of pregabalin and gabapentin in treating postherpetic neuralgia (PHN) patients.Methods A total of 156 hospitalized patients with PHN were dividied into four groups by using a randomized, double-blind method. All groups received a routine therapy of mecobalamin, neurotropin and tramadol, accompanied by different adjuvants regimen. Group A (n=39) received placebo. Group B and group C received oral 225 mg/d and 375 mg/d of pregabalin separately. Group D received oral gabapentin 900 mg/d. All patients received dose titration in the first 5 days, and then the maintenance dose in the following two months. We recorded VAS scores before treatment (T1,baseline), at 1st day (T2), the 2nd day (T3), the 4th day (T4), the 6th day (T5), the 8th day (T6), the 2nd week (T7), the 4th week (T8), the 8th week (T9). And the SPI at T1,EMSIS,treatment outcome and the incidence of adverse events were recorded and at the end of treatment (T10).Results VAS scores of groups B, C, and D were significantly lower than group A (P<0.05),group C was also significantly lower than group D at T5-T9(P<0.05). VAS scores of groups B and C was obviously lower than group D at T7-T9(P<0.05). Compared to group A, the scores of EMSIS of groups B, C, and D were statistically lower (P<0.05). SPI of all the groups at T10 were lower than those at T1, and groups B,C,D were lower than group A while group C was lower than groups B and D.The effective and excellent rates of group A were significantly lower than the other groups and group C was lower than group B and D.Rates of dizziness,somnolence and edema of group B and C were lower than group D(P<0.05).Conclusion Pregabalin could offer better adjuvant analgesic effect on treating neuropathic pain of PHN than gabapentin. Meanwhile, it could improve sleep disorders, life quality, and the PGIC with low incidence of adverse events.